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Abstract Genetic testing is becoming more common and
more powerful by the day. The costs of the underlying
DNA sequencing technology are plummeting, making it
likely that tests based on it will become even more per-
vasive. The use of tests to determine DNA sequence to help
make clinical decisions is here to stay. DNA sequencing is
also finding new uses in forensics, determination of
ancestry, understanding the history and genetic lineages of
human populations and many other applications.
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Biotechnology  Law
Background
Clinical ‘‘genetic tests’’ span a wide range of methods and
uses. One common element is using DNA to infer infor-
mation about the sequence of DNA or RNA in a blood or
saliva sample, or from another biological sample taken
from a person. Such testing can be either to determine that
person’s genetic inheritance (genotype), for example to
predict risk of developing a disease that can be inherited.
Genetic testing can also be done on samples of a tissue or
tumor to identify changes that have occurred in cells in that
person’s body (somatic cell testing), for example to find
DNA changes that have developed in cancer cells.
The general approach is to correlate structural change in
molecules with clinical outcomes, in a field often described
as ‘‘molecular diagnostics,’’ although some uses are not
strictly speaking just for diagnosis, but also for prognosis,
identification of perturbed molecular pathways, guiding
selection of treatments, or determination of cellular origin.
DNA-based testing is as subset of molecular diagnostics.
Molecular diagnostics is broader, encompassing proteins,
lipids, carbohydrates, drug or nutritional metabolites, and
other constituents of cells. This paper concerns only DNA-
based tests, and concerns only patents on individual genes.
Diagnosis and prognosis in clinical medicine are the fore-
most and, to date, most lucrative early applications of genetic
and genomic technologies. Clinical genetic testing is often the
first practical use of gene-based discoveries, once a gene is
cloned and characterized. The prospect of commercial genetic
testing is a major source of both public and private investment.
Clinical genetic testing constitutes a common pathway to
widespread use of genomics, often including commercialization
of DNA-based tests. These medical uses of genetic testing are
affected by many policies, including patent policy, regulation,
and the coding, coverage, and reimbursement of genetic tests.
The Supreme Court Reins in What Can be Patented
This article addresses just one policy domain where
changes have attracted considerable attention: patents on
individual human genes. Several prominent recent cases
have demonstrated clearly how decades of conventional
wisdom about what is and is not patent-eligible was wrong
at the margin, at least in the United States. It turns out that
lawyers confident about the boundaries of what can be
patented in biotechnology have been giving errant advice
to their clients, based on understandings about patent rules
that the US Supreme Court has decisively repudiated.
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While the Court has been clear that DNA molecules and
methods hitherto assumed to be patent-eligible are not, it
has been far from clear in explaining how to draw the line
between what can be patented and what cannot. The Court
unanimously invalidated patent claims that many in the
patent bar assumed were valid claims. That is, the Court
has made clear that some discoveries that many assumed
were patentable are not, including DNA molecules whose
sequences are found in nature. It has not, however, made
clear how much human intervention is needed to convert
unpatentable discoveries into patentable inventions.
Changing jurisprudence is now driving changes in how
researchers, research institutions, and companies engaged
in genetic testing make decisions about whether, when, and
how to patent discoveries and inventions. The business of
patenting genes now faces considerable uncertainty, not
because the Court has changed the rules, but because those
in the patent game had gotten used to a looser set of rules
and now have to adjust to the rules the Supreme Court
asserts should have prevailed all along, but without much
guidance about how to do so.
To understand the nature and cause of that uncertainty,
the history of two recent cases that reached the Supreme
Court is illuminating. The account follows the cases that
were unanimously decided by the Supreme Court in 2012
and 2013. Following those decisions through the US fed-
eral court system conveys the complexity of gene patent
policy, and how hard judges have to work to understand the
legal, technical, medical, and economic stakes affected by
the decisions they are making. The patent cases read like
roller-coasters, with ups and downs and many turns. The
purpose of laying out the details is not just interesting
history, but to show how much uncertainty still pervades
patent policy relevant to genetic diagnostics.
The main upshot of the analysis, however, is clear: the
Supreme Court has repeatedly and unanimously signaled
that patent rights were being granted for unpatentable sub-
ject matter—allowing claims on methods that were too
broad and on DNA molecules that corresponded to
sequences found in nature. In that respect, the law is now
clear: such claims will be ruled invalid. The recent decisions
should thus reduce the shadow of uncertainty cast over ex-
ome sequencing and whole-genome sequencing. That sha-
dow was caused by patent claims that were granted but
appeared to be infringed by any means of making DNA
molecules or determining DNA sequence of the genes being
claimed [see box A]. Infringement would pertain to any form
of whole-genome analysis that included the patented gene,
because in doing such analysis, one would make DNA
molecules from fragments of the patented individual gene as
described in the claims, use methods claimed in individual
gene patents, or do both. The recent court rulings thus clear
the path for unfettered pursuit of whole-genome analysis and
multi-gene methods, although the exact extent of patent
protection conferred by individual gene patents is still being
defined by ongoing litigation that began in July 2013, a
month after the Supreme Court decision in Myriad.
Interaction between Patents, FDA Regulation,
and Coverage and Reimbursement
The main role of patents in biotechnology and medical appli-
cations is to induce private investment in research and devel-
opment (R&D). Most genetic discoveries themselves—efforts
to clone and characterize disease-associated genes or to unravel
metabolic pathways, for example—are based on publicly
funded research conducted at hospitals, non-profit research
institutes, or academic health centers. Such discoveries are
frequently patented, but the patents do not generally add strong
incentives for the discovery of genes; rather the patents are
bundles of rights that can be licensed to firms to develop into
commercial products and services post-discovery.
Only occasionally does private R&D lead to initial gene
discoveries; the patent incentive is relatively weak as a ‘‘pull’’
for initial discovery. The BRCA1 gene associated with breast
cancer and the HFE gene associated with hemochromatosis
were the only genes discovered by private firms among case
studies of dozens of genes underlying ten clinical conditions
prepared for the Secretary’s Advisory Committee for
Genetics Health and Society [1]. This led the Committee to
conclude that ‘‘patent-derived exclusive rights are neither
necessary nor sufficient conditions for the development of
genetic test kits and laboratory-developed tests’’ [2•, p. 35].
The Committee also noted, however, that patents might
become more important if the Food and Drug Adminis-
tration (FDA) begins to more directly regulate laboratory-
developed tests, or if payers require clinical studies to
demonstrate clinical utility before covering and reimburs-
ing genetic tests. FDA premarket approval would make test
development far more expensive than just setting up an
assay, and could warrant patent protection. The relevant
patents, however, are unlikely to be on individual genes.
Patents on sets of genes or specific methods for measuring
DNA changes could interact with FDA regulation as well
as coverage and reimbursement policy. A patent on a
particular FDA-approved test for multiple alleles, for
example, might provide exclusivity on that particular set of
measurements, and a competitor would not have FDA
approval to market the test if it made any significant
modifications (e.g., changing the genes assayed or using a
different interpretive algorithm); in this way, the patent on
a method or set of molecules (but not individual genes)
could provide meaningful exclusivity even as individual
genes are not patent-eligible. This strategy is still open
despite the Supreme Courts rulings described below. The
interaction between patents, regulation, coding, and
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insurance coverage and reimbursement are intricate and
beyond the scope of this review, except to note they merit a
separate analysis in greater depth.
Shifting Sands of Patent Jurisprudence
Patents on genes associated with human disease have been
controversial since they began to be granted. Patents are
government-conferred rights to exclude others from mak-
ing, using, selling, or importing the invention claimed.
They have two parts, a description (or specification) of the
invention and a set of claims that define the boundaries of
the intellectual property. Patent litigation generally centers
on the exact language of patent claims.
The role of patents in diagnostics generated much more
public comment and conflict than patents on genes
encoding known proteins with therapeutic benefit. The
early use of recombinant DNA methods to produce protein
therapeutics such as insulin, growth hormone, tissue plas-
minogen activator, interferon, and erythropoietin included
patents on the genes encoding them [3]. Early gene patents
were granted to ‘‘gene jockeys’’ who cloned and expressed
therapeutic proteins of clinical value. Patents were granted
in all major jurisdictions, although how they were inter-
preted and used differed among the United States, Europe,
Japan, and other jurisdictions. Patents on genes that enco-
ded therapeutic proteins led to patent litigation and legal
conflict, but that was largely confined to battles among
competing companies, rather than public controversy.
Public controversy arose far more in the context of
diagnostic use of patents granted to those who discovered
and characterized disease-associated genes. Policy reports
on ‘‘gene patents’’ began to appear in the early to mid-
1990s, an indicator of emerging policy conflict [4]. The
discovery of genetic changes associated with Huntington’s
disease, Duchenne and Becker muscular dystrophy, cystic
fibrosis, neurofibromatosis, Alzheimer’s disease and other
conditions led to DNA-based diagnostic methods to iden-
tify those at high-inherited risk in families with apparent
Mendelian inheritance patterns. A patent on the ASPA
(aspartoacylase A) gene was granted to Miami Children’s
Hospital, and caused a rift and a lawsuit between the
Hospital and the families and organizations that had
enabled the discovery but disagreed with the Hospital’s
commercialization strategy [5, 6]. That lawsuit did not
challenge the patent directly, however, but alleged breach
of informed consent and unjust enrichment.
Early BRCA Patent Litigation
The patenting of the BRCA1 and BRCA2 genes, on chro-
mosomes 17 and 13, respectively, bred by far the most
conspicuous and intense controversy in gene patent policy.
BRCA testing was mentioned far more often than any other
case in policy reports on gene patent policy [4], and cov-
erage in general newspapers in English-speaking countries
was overwhelmingly negative [7], even before it became
the subject of high-profile litigation in 2009.
Litigation over BRCA patents began in 1997 [8]. On-
corMed sued Myriad Genetics alleging infringement of a
patent on the consensus sequence of BRCA1 granted to
OncorMed in August. Myriad countersued the day after it
got its first BRCA1 patent in December. Myriad also filed
(but never fully served) a lawsuit against the University of
Pennsylvania. The University quickly agreed not to do
testing except for its own patients; OncorMed and Myriad
settled out of court on terms that were not made public [9].
These legal skirmishes attracted some media attention, but
the real controversy swirling around Myriad Genetics and
its BRCA gene patents centered on its business model and
the way it used its patent rights [8, 9].
Nine laboratories that had been offering BRCA testing
withdrew from the US market [10], and no one challenged
Myriad’s patents for a decade. Myriad Genetics became the
only commercial BRCA testing laboratory in the United
States, although its service monopoly did not become
established in any other country [9, 11, 12]. Through 2013,
Myriad performed over one million BRCA tests and gen-
erated over $2.8 billion in revenues.1
Mayo v Prometheus: a Supreme Court Decision
about Diagnostic Method Claims
The stage for the famous Myriad case that went to the
Supreme Court was set by several other cases bearing on
diagnostics, although not specifically DNA diagnostics. In
2006, the Supreme Court agreed to hear, but then ulti-
mately decided not to rule on LabCorp v Metabolite. The
patent in question was on a test measuring levels of
homocysteine to evaluate the likelihood of deficiencies in
folate and cobalamin (vitamins B6 and B12). The Supreme
Court’s finding was one terse sentence saying its grant of
appeal had been ‘‘improvidently granted,’’ and declining to
rule on the case. The only explanation and extended prose
was a spirited dissent written by Justice Breyer, joined by
Justices Souter and Stevens. The dissenters invited a future
case that would center on diagnostic methods that depen-
ded on correlations and raised questions of patentable
subject matter [13].
Another case seeming to partly answer Justice Breyer’s
invitation came several years later in the form of Mayo v
1 Number of tests taken from Myriad public statement to the US
Patent and Trademark Office in January 2013; revenues from 10 K
and annual reports compiled by the author.
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Prometheus. The patent that Mayo challenged in that case
involved a method for measuring metabolites to adjust the
dose of thiopurine drugs (used as anti-inflammatory treat-
ments). The Court of Appeals for the Federal Circuit had
twice upheld claims on the patented method. The Supreme
Court ruled unanimously that the claims were invalid
because the method reached to a law of nature. This ruling
had implications for genetic diagnostics, because method
claims were often the broadest and hardest to work around
in gene patents [14–16]. The Mayo ruling meant that many
of the claims granted on individual genes, where they
covered any way of measuring a sequence variant, would
be ruled invalid if challenged.
The BRCA Case that Went to the Supreme Court
Even as Mayo was making its way through the courts, the
legal landscape was changing on another front, this time
centered specifically on DNA molecules (as opposed to
methods). In May 2009, the American Civil Liberties
Union (ACLU) and Public Patent Foundation filed suit
against Myriad Genetics, the US Patent and Trademark
Office and the University of Utah [17]. That suit, filed in
New York’s Federal District Court in Manhattan, followed
a two-year process of deliberation within ACLU to decide
whether and how to directly challenge human gene pat-
enting as a matter of public interest law.2 ACLU gathered
20 plaintiffs: women wanting to get tested, physicians
wanting to order tests, laboratory directors wanting to offer
BRCA testing, and organizations [18]. The Association for
Molecular Pathology was first to agree to sign onto the suit,
and became the lead plaintiff.
Federal District Court Decision
In a remarkable happenstance, the case was assigned to
Judge Robert Sweet, who at the time had a clerk, Herman
Yeu, with a background in molecular biology and a PhD
from the University of California, Berkeley [19]. In March
2010, Judge Sweet rocked the patent world by ruling that
all fifteen claims in the seven Myriad patents challenged in
the lawsuit were invalid. He did this via summary judg-
ment (without a trial) as a matter of law, basing his deci-
sion on Section 101 of the US patent statute that defines
what can be patented. That is, he ruled that the claims did
not clear the threshold of patentable subject matter, without
even getting to the factual questions about other patent
criteria: novelty, utility, nonobviousness, enablement and
written description [20•].
There were three basic classes of claims. Some claims
were on DNA molecules constituting the gene encoding
BRCA1 and BRCA2 proteins; others were methods of
detecting alterations in the sequence; and one challenged
claim was for a method of using BRCA1 as part of a cancer
drug assay. Judge Sweet found that the claims on DNA
molecules were invalid because ‘‘DNA represents the
physical embodiment of biological information, distinct in
its essential characteristics from any other chemical found
in nature’’ and therefore unpatentable [20•] (at pp. 2–3). He
rejected the argument that the DNA molecules claimed
were patentable because they were ‘‘isolated,’’ noting that
some called that a ‘‘lawyer’s trick.’’ As to the method
claims, he judged ‘‘the claimed comparisons of DNA
sequences are abstract mental processes [that] constitute
unpatentable subject matter.’’
Court of Appeals for the Federal Circuit Decisions
Myriad appealed Judge Sweet’s district court decision to
the Court of Appeals for the Federal Circuit (CAFC), a
special court that Congress established in 1982. CAFC
hears patent appeals from all district courts. The case went
to a three-judge panel of Alan Lourie, Kimberly Moore,
and William Bryson. Judge Lourie wrote the majority
opinion that had four major components: (1) it concurred
with judge Sweet’s invalidation of five of the six method
claims; (2) it held that only one plaintiff, Harry Ostrer, had
standing to sue; (3) it upheld the one method claim on use
of BRCA1 in a cancer drug assay; and (4) it reversed Judge
Sweet to uphold nine claims on DNA molecules. The first
three components were unanimous.
On the fourth point—whether the DNA molecule claims
were patentable subject matter—the three judges split 2-1.
Judges Lourie and Moore agreed DNA molecules could be
patented, but disagreed about why and how. Judge Lourie
reasoned the molecules were structurally different from
those found in chromosomal DNA because covalent bonds
were broken; Judge Moore found that fragments of DNA
had uses that native DNA does not share, although she also
noted that one reason persuading her to uphold the claims
was that business decisions had rested on settled under-
standings that ‘‘isolated’’ DNA is patentable subject matter.
She indicated her decision might be different had not so
many claims of this type been granted over three decades.
Judge Bryson dissented. He agreed that some DNA
molecules could be patented, if they were altered to a form
not found in nature, such as complementary DNA (cDNA)
2 Interviews with Chris Hansen (ACLU), Lori Andrews (Kent School
of Law), Tania Simoncelli (ACLU), and Sandra Park (ACLU) and
summarized in Alexandra Young 18.Young, A., Prelude to ‘Pigs
Fly:’ The Early History of the Myriad Case,undergraduate thesis
outside the disciplines, in Thesis Outside the Disciplines. 2014, Duke
University: Durham, NC. See also 19.Jasanoff, S., Dis-Owning
Nature: The BRCA Gene Patents and the Supreme Court, in Program
on Science, Technology and Society, Harvard Kennedy School, S.
Jasanoff, Editor. 2013: Cambridge, MA.
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sequences lacking introns. But he argued claims to a DNA
molecule whose sequence was found in nature were not
patentable. Bryson noted, ‘‘In its simplest form, the ques-
tion in this case is whether an individual can obtain patent
rights to a human gene. From a common-sense point of
view, most observers would answer, ‘Of course not. Patents
are for inventions. A human gene is not an invention’’’ [21]
(pp. 2–3 of Bryson dissent). He went on to argue that the
DNA molecules claimed were identical in sequence to
those in the body, or their utility as diagnostics would be
lost, and DNA molecules whose sequence was found in
nature were not eligible to be patented.
Appeal to the Supreme Court
The case was appealed to the Supreme Court, which in the
meantime had ruled in Mayo v Prometheus (see above).
The Supreme Court remanded Myriad to the CAFC for
reconsideration in light of Mayo. The CAFC panel reaf-
firmed its previous decision, with the same 2-1 split over
whether DNA molecule claims were patent-eligible. The
Supreme Court agreed to hear another appeal in its
2012–2013 term, considering just one four-word question:
‘‘Are human genes patentable?’’ [22]. Oral arguments took
place on April 15, 2013, and the Supreme Court handed
down its ruling on June 13 [23••].
Judge Clarence Thomas wrote the unanimous (9-0)
opinion, which ruled that ‘‘A naturally occurring DNA
segment is a product of nature and not patent-eligible
merely because it has been isolated, but cDNA is patent-
eligible because it is not naturally occurring’’ [23••] (p. 2).
The Supreme Court’s arguments tracked closely to CAFC
Judge Bryson’s dissent, and friend-of-the-court briefs filed
by the US Solicitor General on behalf of the US Govern-
ment, which argued that cDNA was patent-eligible, but
DNA molecules corresponding to sequences found in a
genome were not [24, 25].
Litigation Since the Supreme Court Decision
The Supreme Court decision did not end the litigation
battles over BRCA testing. On the day of the ruling, Ambry
Genetics and Gene by Gene both announced they were
offering BRCA testing services. Other laboratories indi-
cated they intended to do so. Many laboratories now offer
BRCA testing in the United States (see Table 1).
Even before the Supreme Court decision, Myriad
Genetics issued public statements that it had over 500
claims in 23 patents, most of which were not challenged by
the ACLU. Myriad began filing lawsuits against firms that
offered BRCA testing. On July 9, 2013, Myriad sued
Ambry Genetics in federal district court in Utah. The next
day, Myriad filed a similar suit against Gene by Gene.
Myriad has since filed suits against Quest Diagnostics,
Labcorp, Invitae, GeneDx, and Pathway Genomics. Some
of those firms filed requests for declaratory judgment of
non-infringement in California federal district courts. The
pretrial proceedings have been consolidated in the Salt
Lake City, Utah, court of Judge Robert Shelby, by order of
a panel of judges who decide the disposition of cases that
involve multiple district courts [26]. All of the cases
include BRCA testing; some also cover patents on MUTYH,
a gene involved in some forms of inherited colorectal and
other cancers.
In February, 2014, Gene by Gene settled with Myriad,
and agreed not to offer BRCA testing in the United States.
In March 2014, Judge Shelby denied Myriad’s motion for a
preliminary injunction against Ambry [27•]. If Judge
Shelby had granted the injunction, Ambry would have had
to stop offering BRCA testing while the litigation was
underway, and Myriad’s other competitors would likely
have done likewise. By denying the injunction, Ambry can
remain in the market, although it could still lose the case
and could be forced to pay damages to Myriad.
Judge Shelby’s ruling directly addressed the likelihood
that Myriad would prevail in its various lawsuits; his ruling
is skeptical that the DNA molecule claims on primers and
probes, or on amplification methods, will be upheld. Judge
Shelby held a case management hearing in April 2014. He
dismissed Ambry’s antitrust claims against Myriad [28].
He also set a deadline for further pleadings of July 1, 2014,
set a deadline for the discovery process in which litigants
gather documents and other materials in February 2015,
and set limits on the number and duration of categories of
witnesses [29]. That is, he set rules for any subsequent
trials and the discovery process for fact-finding and
documentation.
In parallel, Myriad has appealed Judge Shelby’s denial
of an injunction to the CAFC. If CAFC affirms Judge
Shelby, then any trials would proceed while competition
continues in the BRCA testing marketplace; if CAFC
reverses Judge Shelby, then Ambry would have to exit the
market, and other companies would likely to do likewise.
These trials are in a race against patent expiration, with the
first of the patents-in-suit expiring in August 2014 and the
ten broadest patents set to expire by the end of 2015. If they
go to trial and proceed through the court system, they may
help to clarify the boundaries of what is patentable and
what is not, and may also make public some of the history
of scientific discovery of the relevant genes because of the
rigorous legal discovery process and court proceedings.
Finally, in August 2014, GeneDx, one of the defendants
sued by Myriad for patent infringement, filed eleven peti-
tions at the US Patent and Trademark Office, seeking
reexamination of claims in 11 patents [30]. This is an
administrative procedure that cannot challenge patentable
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subject matter, but raises questions of novelty, nonobvi-
ousness, enablement and written description. It will pro-
ceed in parallel to the litigation already underway.
Summary and Conclusion
A series of recent Supreme Court decisions have chal-
lenged the conventional wisdom and legal expectations
about what can be patented. Ongoing litigation and future
cases will further refine patent law, not only what can be
patented but perhaps also how criteria will be applied to
determine when an invention is new, useful, nonobvious,
fully enabled, and adequately described.
The technologies for measuring DNA and proteins have
moved rapidly in recent decades, as have methods for
accumulating, digitizing, storing, and analyzing data. The
analysis of the information that results of testing is at least
as complex and difficult as generating the data, and it is
essential to clinical interpretation. Indeed, the profusion of
data is bringing the importance of algorithms and compu-
tational methods to the fore. Such methods can also be
patented, regulated, or paid for as services. The focus of
this chapter, however, is on genetic tests to determine the
sequence taken from a body sample.
Four main conclusions can be drawn from this history.
First, the Supreme Court has made clear that patent practice
for three decades has entailed granting exclusive rights that
are too broad and cover products of nature and laws of
nature. Two unanimous decisions about diagnostic tech-
nologies have narrowed the range of patentable subject
matter of both methods and DNA molecules. Second, the
boundaries of patentable subject matter are still fuzzy. The
Supreme Court has unanimously ruled that lower courts
were upholding patents claims they should not have upheld,
but it has not indicated how to draw the line between
methods and molecules that are patent-eligible and those
that are not. Third, the Court’s decisions reduce the risk of
infringement liability for multi-gene and whole-genome
analysis. It is not clear where the line is or how many genes
one needs to test to avoid infringement liability, but it is
highly likely that those holding patent claims on individual
genes will not be able to enforce them against whole-gen-
ome analysis. Finally, and most directly relevant to the
future of genetic testing, the Supreme Court has clearly
noted that it will permit patents on some DNA inventions.
Such patents will not likely be on individual genes, however,
but on technologies and methods that more clearly reflect the
art of invention rather than the labor of discovery.
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